This program prepares pre- and post-doctoral individuals for careers as independently-funded researchers and for leadership in global HIV implementation research. The fellowship provides support two or three years and offers: mentoring and research support, didactic coursework in epidemiology and implementation science, networking, assistance with grant writing and manuscript preparations, and funds for travel and research-related expenses. (funded by NIH)

Visit the Student Resources page for more information and to apply

HPTN 076 is a two-year study that is recruiting over 130 sexually active women age 18 to 45 and evaluating the safety and acceptability of a new injectable HIV prevention medication, Rilpivirine, for use in healthy, HIV-uninfected women. (funded by the NIH)

HVTN 704/HPTN 085 is a five-year study testing the safety, tolerability, and prevention benefit of a manufactured antibody (VRC01) against HIV. The study aims to recruit about 2,700 participants from sites in the U.S. and South America. The Bronx Prevention Center will serve as one of the U.S. sites and will recruit HIV-uninfected men and transgender women who have sex with men. (funded by the NIH)

The program is a fully-funded, research-focused summer fellowship that provides students from underrepresented and minority backgrounds with international research placements, training and mentorship in global health and health disparities. (funded by NIH)

Visit the Student Resources page for more information and to apply

This five-year, multi-method implementation study tests an enhanced PrEP adherence package against a standard package in a randomized clinical trial located in a community setting. The study compares the effectiveness of both approaches, assessing patterns and monitoring changes in risk behaviors among black men who have sex with men (MSM) and transwomen participants taking PrEP. (funded by NIH)

The ADAPT Study recruited men who have sex with men (MSM) and transgender women and is designed to identify oral pre-exposure prophylaxis (PrEP) pill-taking schedules that participants are more likely to follow and determine if these schedules influence healthier sexual practices. (funded by NIH)

This study investigated the experimental microbicide gel tenofovir to protect women against HIV. The study provided information on how much vaginal tenofovir gel, when used in combination with common vaginal products, will interfere with the local and or systemic exposure of the tenofovir, and vice versa, to optimize effectiveness as an HIV prevention tool. (funded by CONRAD)

This study examined the drug levels of the antiretroviral agent tenofovir in rectal tissue after it has been used as a gel in the vagina and vice versa. (funded by NIH)